AstraZeneca Group News

Simon Lowth, the chief financial officer of AstraZeneca, sold nearly 665,000 worth of his shares in the drugs giant after the company announced a fall in earnings and a major restructuring.

A U.S. appeals court upheld a lower court's dismissal of certain AstraZeneca PLC patent-infringement lawsuits against several generic manufacturers that are planning to sell copies of the company's blockbuster cholesterol-lowering drug Crestor.

Pharmaceutical companies remain under pressure as they deal with increased competition from each other, which threatens their market share.

A PHARMACEUTICALS giant which employs hundreds of Knutsford people has announced it is to axe more than 7,000 jobs by the end of 2014 - a move that has been criticised by Tatton's Labour party.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Stomach Acid Drugs Including AstraZeneca PLC 's Nexium and Santarus Inc.

GlaxoSmithKline released fourth-quarter 2011 and full-year financial results Tuesday, which happens to be Charles Dickens' birthday.

The National Association for Female Executives today named AstraZeneca one of the top 50 companies for female executives for the fourth consecutive year.

AstraZeneca was downgraded by equities research analysts at Bank of America from a "neutral" rating to an "underperform" rating in a research note issued to investors on Tuesday.

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 8 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 478,287 ordinary shares of AstraZeneca PLC at a price of 2997 pence per share on 6 February 2012.

So far this has been a great year for biotech, as investors have been more than happy to look past the risks and embrace the opportunities in the pipeline.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia February 3, 2012 -- Steve Yang, AstraZeneca's high profile VP and Head of R&D for Asian and Emerging Markets, is setting an ambitious goal for the company's China R&D ... (more)

After a week of speculation AstraZeneca officially announced plans to eliminate thousands of jobs as part of a restructuring designed to save the company $1.6 billion annually by 2014.

From several reports, here's what I have on AstraZeneca's plans in Waltham: they've told people there that cuts are coming.

From 7,300 new job cuts to a contracting cost base and lower revenue guidance, in many ways AstraZeneca is the incredible shrinking company.

Major Pharmaceutical companies have seen their profits drop in recent quarters as patent protection on their largest products continues to shrink revenues.

Crestor, a cholesterol-lowering drug, was a top performer for AstraZeneca in 2011, helping the company post a $10 billion profit, up from $8.1 billion in 2010.

It's no secret that Big Pharma companies live and die with their pipeline and their ability to drive sales from patent-protected branded drugs.

The health challenges of China and Asia offer big opportunities for multinational pharma companies.

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 2 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 467,081 ordinary shares of AstraZeneca PLC at a price of 3068 pence per share on 1 February 2012.

Union bosses have warned that job cuts by pharmaceuticals giant AstraZeneca will be a blow to the UK economy and have vowed to minimise compulsory redundancies.